CLEC1B and COVID-19: Furthermore, podoplanin‐CLEC2 interaction contributes to venous thrombosis (Suzuki‐Inoue, 2017), suggesting blockade of podoplanin‐mediated inflammation by CLEC2.Fc may be able to reduce the risk of vascular microthrombosis in COVID‐19 patients.